Preliminary data "Colchicine is an FDA-approved drug that we identified with high throughput screening". This sentence is unclear, because there is no reference. Did the authors perform screening? Mention more details about the selection of this specific compound for this clinical trial. On the other hand, the following background info is too lengthy.
Primary objective Which ALSFRS-R was to be used, the English or Italian version?
REVIEWER
Bjorn Oskarsson Mayo Clinic Jacksonville USA REVIEW RETURNED 08-Jan-2019 I am very much looking forward to the results of this exciting project.
GENERAL COMMENTS

VERSION 1 -AUTHOR RESPONSE
Reviewers' Reports:
Reviewer: 1
Reviewer Name: Hiroyuki Nodera Institution and Country: Tokushima University, Japan
Please state any competing interests or state 'None declared': None declared This is a well-planned clinical trial. This reviewer has some minor comments.
We shortened the preliminary data section and added the information required (page 5).
Colchicine is an FDA-approved drug that we identified in an high throughput screening performed by us utilizing the promoter region of the HSPB8 gene as explained in "Crippa V, D'Agostino VG, Cristofani R, et al. Colchicine is known to cause an autophagic vacuolar myopathy, sharing many similarities with VCP and SQSTMI which can cause similar problems. At the some point in the discussion I would like to see this potential problem/backside of increased autophagy mentioned. I doubt that this will become a problem during the trial but would want to call attention to this possible issue. A reference such as the following would be reasonable;
Ching JK, Elizabeth SV, Ju JS, Lusk C, Pittman SK, Weihl CC. mTOR dysfunction contributes to vacuolar pathology and weakness in valosin-containing protein associated inclusion body myopathy. Hum Mol Genet 2013.
The author makes a valid point. We added the observation in the biological assessment section (page 9): "quantification of mRNA and protein levels of p62, LC3, TFEB, ATGs, HSPB8, BAG3, BAG1, HSP70, and HSF1, in patients' PBMCs, lymphoblasts and fibroblasts (transcriptome profile); [32] we will test this profile also in available muscle biopsy (optional for patients); particular attention will be paid to possible formation of autophagic vacuoli which may resemble those identified in IBMPFD/ALS possibly associated to autophagy iperactivation" and added the corresponding reference.
-I agree with the concept of trying to reduce phenotypic variability. Trying to more explicitly define the concepts of "classical" and "bulbar" phenotype as compared to more slowly progressive variants of the disease would be desirable. Many patients do not fall neatly into 1 category and a formal process for determining phenotypic eligibility would be useful in those few patients to reduce variability in this multi center project.
The reviewer makes a very good point. We added the definition of classical and bulbar phenotypes in the manuscript (page 7) as follows (Chiò et al., 2011): Classic phenotype: is characterised by onset of symptoms in the upper or lower limbs, with clear but not predominant pyramidal signs associated to lower MN signs. Patients with characteristics that may evolve in flail arm, flail leg or UMN-p phenotypes should be excluded.
Bulbar phenotype: these patients have a bulbar onset with dysarthria and/or dysphagia, tongue wasting, fasciculation and limited spinal involvement for the first months after symptoms onset. Pyramidal signs are not required to be evident at the beginning but need to be evident thereafter.
-
The duration of fasting prior to IMP dosing could be defined.
Fasting should be of at least 3 hours (before breakfast and before dinner). We added this is the paper (page 8)
If bitter oranges are popular in Italy then a mentioning of them in the CYP3A4 inhibiting section would be reasonable.
We agree with the reviewer and we added this in the text (page 10).
Tracheostomy free survival is an outcome dependent on the frequency of use of tracheostomy. If a center rarely utilizes tracheostomy instead relying on 24/7 NIV then this outcome would be skewed. I would suggest the addition of NIV use greater than 22 hr per day as a death equivalent.
We agree with the reviewer and we added NIV>22 h/day to the other outcomes (in Italy 15% of patients undergo tracheostomy)(page 9).
VERSION 2 -REVIEW
REVIEWER
Bjorn Oskarsson Mayo Clinic, Jacksonville REVIEW RETURNED 03-Mar-2019
GENERAL COMMENTS
The minor suggestions have been addressed
